Edwards Lifesciences Corp 8K

Edwards Lifesciences reported strong Q2 2026 results with double‑digit sales and adjusted EPS growth and raised its 2026 sales guidance across key structural heart product lines while reaffirming full‑year adjusted EPS expectations.

On July 23, 2026, Edwards Lifesciences Corporation reported its financial results for the quarter ended June 30, 2026, announcing 13.6% year-over-year net sales growth to $1.74 billion (12.5% on a constant currency basis), driven primarily by 11.3% growth in Transcatheter Aortic Valve Replacement (TAVR) sales to approximately $1.26 billion and a 47%+ increase in Transcatheter Mitral and Tricuspid Therapies (TMTT) sales to about $196 million, alongside 6.5% growth in Surgical sales. The company reported GAAP diluted EPS of $0.42 and adjusted EPS of $0.78, with an adjusted operating margin of 30.0% and gross margin of 77.6%. Based on the stronger-than-expected Q2 performance, Edwards raised its 2026 full-year guidance, increasing total company constant-currency sales growth guidance to 10%–11%, TAVR growth guidance to 8%–9%, and TMTT sales guidance to $760–$780 million, while reaffirming adjusted EPS guidance of $2.95–$3.05 despite expecting its effective tax rate to be at the high end of the prior 16%–19% range due primarily to a new California law limiting R&D credit usage. The release also highlighted continued global adoption of the company’s SAPIEN platform and structural heart portfolio, favorable long-term clinical data across TAVR and surgical RESILIA tissue, an expected CMS National Coverage Determination update for TAVR in September, anticipated regulatory approvals for next‑generation PASCAL and a new PASCAL tricuspid indication in Q4 2026, the ongoing rollout of EVOQUE and SAPIEN M3 systems, an approval of the ECLIPTIS surgical left atrial appendage system in the U.S., and confirmed cash and equivalents of approximately $2.9 billion, total debt of about $600 million, and $1.5 billion remaining under its share repurchase authorization.

Filing Facts

CIK

1099800

Ticker

EW

Form

8K

Source Type

sec

Accession

0001099800-26-000038

Alert Tier

7